Introduction
This study aimed to determine the frequency of transactive response DNA binding protein 43 kDa (TDP-43) pathology in PSP, the clinical features of patients with this pathology, and genetic risk factors for it..
Methods
Hippocampal sections were screened with immunohistochemistry for TDP-43 in 945 PSP cases. A subset of 261 cases that were negative in hippocampus was screened in the amygdala. The density and disruption of this pathology, as well as regional tau burden, and clinical and genetic characteristics were analyzed.
Results
We observed TDP-43pathology in 47 cases in the hippocampus and an additional 9 cases that only affected the amygdala. Hippocampal sclerosis was the strongest risk factor, followed by Alzheimer’s disease pathology, argyrophilic grain disease, and older age at death. Five stages of TDP-43 pathology were identified in PSP: Stage A had pathology only in the amygdala (16%); stage I had pathology confined to the hippocampus and entorhinal cortex (9%); stage II included both regions of stage A and I (38%); stage III spread further to medial occipitotemporal gyrus (20%); and stage IV had pathology in the dorsolateral frontal lobe (18%). Anatomical areas vulnerable to PSP pathology had varying degrees of this pathology in stage II and later. PSP with TDP-43pathology were older at disease onset and had lower median MMSE scores; however, the latter was driven by concurrent pathologies.
Conclusions
Distribution and clinical characteristics of TDP-43pathology in PSP were influenced by concurrent pathologies. This is the first study to observe that PSP-vulnerable regions are also susceptible to this non-tau pathology.